A61K 35/17
Lymphocytes
Official title: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
A61K35/17 (Lymphocytes) appears on 1,710 US grants and 4,108 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,710
- Published applications
- 4,108
- Assignees
- 1,359
- Inventors
- 6,646
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1979 | 2 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 2 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 4 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 1 |
| 2002 | 1 | 4 |
| 2003 | 0 | 4 |
| 2004 | 1 | 5 |
| 2005 | 2 | 12 |
| 2006 | 3 | 9 |
| 2007 | 2 | 14 |
| 2008 | 1 | 8 |
| 2009 | 4 | 9 |
| 2010 | 4 | 19 |
| 2011 | 7 | 19 |
| 2012 | 5 | 22 |
| 2013 | 9 | 39 |
| 2014 | 16 | 36 |
| 2015 | 26 | 55 |
| 2016 | 34 | 80 |
| 2017 | 36 | 130 |
| 2018 | 76 | 170 |
| 2019 | 149 | 311 |
| 2020 | 188 | 355 |
| 2021 | 205 | 379 |
| 2022 | 169 | 391 |
| 2023 | 151 | 374 |
| 2024 | 308 | 631 |
| 2025 | 174 | 604 |
| 2026 | 116 | 427 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Anti-Claudin18.2 antigen-binding fragment or antibody, and use thereof182551196 Oct 2026US 12,751,972 B2Guangzhou Bio-Gene Technology Co., Ltd
- Bispecific chimeric antigen receptors targeting CD20 and BCMA6 Oct 2026US 12,751,973 B2Abelzeta Inc.
- Methods for treating pancreatic cancer and other solid tumors6 Oct 2026US 12,751,991 B2Lisata Therapeutics, Inc.
- Inducible chimeric antigen receptor and application thereof6 Oct 2026US 12,752,007 B2Beijing Tiantan Hospital, Capital Medical University
- Anti-tumor necrosis factor receptor (TNFR2) antibodies and uses thereof6 Oct 2026US 12,753,240 B2Biolojic Design Ltd.
- Composition for inducing immunotolerance8 Oct 2026US 2026/0306540 A1
- Novel phosphoantigen prodrug compound and use thereof8 Oct 2026US 2026/0306541 A1
- Targeted Immune Cell Therapy Utilizing TRAIL and TNF Mediated Apoptosis8 Oct 2026US 2026/0306542 A1Northeastern University
- Intra-striatal co-transplantation of autologous treg and mda cells in parkinson's disease cell therapy8 Oct 2026US 2026/0306543 A1The McLean Hospital Corporation
- Cd28h domain-containing chimeric antigen receptors and methods of use8 Oct 2026US 2026/0306544 A1The United States of America, as represented by the Secretary, Dept. of Health and Human Services
Most cited
By later US patents
- Handheld electromechanical surgical system627US 10,932,784 B2Covidien LP · 2021
- Platelet glue wound sealant215US 5,733,545 AQuantic Biomedical Partners · 1998
- Immunotherapy against several tumors, such as lung cancer, including NSCLC198US 10,071,148 B2Immatics Biotechnologies GmbH · 2018
- Immunotherapy against several tumors, such as lung cancer, including NSCLC131US 9,943,579 B2Immatics Biotechnologies GmbH · 2018
- Immunogenic epitope for immunotherapy117US 8,080,634 B2Immatics Biotechnologies GmbH · 2011